drugset / Trial / NCT00559975
Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine
RandomizedParallel-groupSingle-blindPrevention
Summary
To evaluate the safety and tolerability of the an adjuvanted influenza vaccine combined with CpG7909 at three different doses of CpG 7909 as a single intramuscular (IM) administration in healthy adults. Safety will be assessed by observation of symptoms, physical examination findings and laboratory safety testing.
Timeline
- Start
- 2007-10
- Primary completion
- —
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adjuvanted influenza vaccine | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Subunit Influenza Vaccine | Vaccine | 0.5 ml | — |
| Subject | agatolimod | Oligonucleotide (other) | 10 ug | Intramuscular |
| Subject | agatolimod | Oligonucleotide (other) | 30 ug | Intramuscular |
| Subject | agatolimod | Oligonucleotide (other) | 100 ug | Intramuscular |